|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kantono M and Guo B: Inflammasomes and
cancer: The dynamic role of the inflammasome in tumor development.
Front Immunol. 8:11322017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okamoto M, Liu W, Luo Y, Tanaka A, Cai X,
Norris DA, Dinarello CA and Fujita M: Constitutively active
inflammasome in human melanoma cells mediating autoinflammation via
caspase-1 processing and secretion of interleukin-1beta. J Biol
Chem. 285:6477–6488. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nasti TH and Timares L: Inflammasome
activation of IL-1 family mediators in response to cutaneous
photodamage. Photochem Photobiol. 88:1111–1125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rathinam VAK and Fitzgerald KA:
Inflammasome complexes: Emerging mechanisms and effector functions.
Cell. 165:792–800. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Zoete MR, Palm NW, Zhu S and Flavell
RA: Inflammasomes. Cold Spring Harb Perspect Biol. 6:a0162872014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lamkanfi M: Emerging inflammasome effector
mechanisms. Nat Rev Immunol. 11:213–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martinon F, Burns K and Tschopp J: The
inflammasome: A molecular platform triggering activation of
inflammatory caspases and processing of proIL-beta. Mol Cell.
10:417–426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Frew BC, Joag VR and Mogridge J:
Proteolytic processing of Nlrp1b is required for inflammasome
activity. PLoS Pathog. 8:e10026592012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nour AM, Yeung YG, Santambrogio L, Boyden
ED, Stanley ER and Brojatsch J: Anthrax lethal toxin triggers the
formation of a membrane-associated inflammasome complex in murine
macrophages. Infect Immun. 77:1262–1271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Faustin B, Lartigue L, Bruey JM, Luciano
F, Sergienko E, Bailly-Maitre B, Volkmann N, Hanein D, Rouiller I
and Reed JC: Reconstituted NALP1 inflammasome reveals two-step
mechanism of caspase-1 activation. Mol Cell. 25:713–724. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Van Opdenbosch N, Gurung P, Vande Walle L,
Fossoul A, Kanneganti TD and Lamkanfi M: Activation of the NLRP1b
inflammasome independently of ASC-mediated caspase-1
autoproteolysis and speck formation. Nat Commun. 5:32092014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guey B, Bodnar M, Manié SN, Tardivel A and
Petrilli V: Caspase-1 autoproteolysis is differentially required
for NLRP1b and NLRP3 inflammasome function. Proc Natl Acad Sci USA.
111:17254–17259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bauernfeind F and Ablasser A:
Inflammasomes: Current understanding and open questions. Cell Mol
Life Sci. 68:765–783. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Finger JN, Lich JD, Dare LC, Cook MN,
Brown KK, Duraiswami C, Bertin J and Gough PJ: Autolytic
proteolysis within the function to find domain (FIIND) is required
for NLRP1 inflammasome activity. J Biol Chem. 287:25030–25037.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu CH, Moecking J, Geyer M and Masters SL:
Mechanisms of NLRP1 mediated autoinflammatory disease in humans and
mice. J Mol Biol. 430:142–152. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lamkanfi M and Dixit VM: Mechanisms and
functions of inflammasomes. Cell. 157:1013–1022. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kayagaki N, Warming S, Lamkanfi M, Vande
Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S, et al:
Non-canonical inflammasome activation targets caspase-11. Nature.
479:117–121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li
P, Hu L and Shao F: Inflammatory caspases are innate immune
receptors for intracellular LPS. Nature. 514:187–192. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu X and Lieberman J: A mechanistic
understanding of pyroptosis: The fiery death triggered by invasive
infection. Adv Immunol. 135:81–117. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao D, Wu Y, Zhuang J, Xu C and Zhang F:
Activation of NLRP1 and NLRP3 inflammasomes contributed to cyclic
stretch-induced pyroptosis and release of IL-1β in human
periodontal ligament cells. Oncotarget. 7:68292–68302. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feldmeyer L, Keller M, Niklaus G, Hohl D,
Werner S and Beer HD: The inflammasome mediates UVB-induced
activation and secretion of interleukin-1beta by keratinocytes.
Curr Biol. 17:1140–1145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hasegawa T, Nakashima M and Suzuki Y:
Nuclear DNA damage-triggered NLRP3 inflammasome activation promotes
UVB-induced inflammatory responses in human keratinocytes. Biochem
Biophys Res Commun. 477:329–335. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Strittmatter GE, Sand J, Sauter M,
Seyffert M, Steigerwald R, Fraefel C, Smola S, French LE and Beer
HD: IFN-γ primes keratinocytes for HSV-1-induced inflammasome
activation. J Invest Dermatol. 136:610–620. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reinholz M, Kawakami Y, Salzer S, Kreuter
A, Dombrowski Y, Koglin S, Kresse S, Ruzicka T and Schauber J:
HPV16 activates the AIM2 inflammasome in keratinocytes. Arch
Dermatol Res. 305:723–732. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ekman AK, Verma D, Fredrikson M, Bivik C
and Enerbäck C: Genetic variations of NLRP1: susceptibility in
psoriasis. Br J Dermatol. 171:1517–1520. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bivik C, Verma D, Winge MC, Lieden A,
Bradley M, Rosdahl I and Söderkvist P: Genetic variation in the
inflammasome and atopic dermatitis susceptibility. J Invest
Dermatol. 133:2486–2489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Levandowski CB, Mailloux CM, Ferrara TM,
Gowan K, Ben S, Jin Y, McFann KK, Holland PJ, Fain PR, Dinarello CA
and Spritz RA: NLRP1 haplo-types associated with vitiligo and
autoimmunity increase interleukin-1β processing via the NLRP1
inflammasome. Proc Natl Acad Sci USA. 110:2952e29562013. View Article : Google Scholar
|
|
29
|
Faustin B and Reed JC: Sunburned skin
activates inflammasomes. Trends Cell Biol. 18:4–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Faustin B, Chen Y, Zhai D, Le Negrate G,
Lartigue L, Satterthwait A and Reed JC: Mechanism of Bcl-2 and
Bcl-X(L) inhibition of NLRP1 inflammasome: Loop domain-dependent
suppression of ATP binding and oligomerization. Proc Natl Acad Sci
USA. 106:3935–3940. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reagan-Shaw S, Breur J and Ahmad N:
Enhancement of UVB radiation-mediated apoptosis by sanguinarine in
HaCaT human immortalized keratinocytes. Mol Cancer Ther. 5:418–429.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sand J, Haertel E, Biedermann T, Contassot
E, Reichmann E, French LE, Werner S and Beer HD: Expression of
inflammasome proteins and inflammasome activation occurs in human,
but not in murine keratinocytes. Cell Death Dis. 9:242018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gurung P and Kanneganti TD:
Autoinflammatory skin disorders: The inflammasome in focus. Trends
Mol Med. 22:545–564. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu-Bryan R: Intracellular innate immunity
in gouty arthritis: Role of NALP3 inflammasome. Immunol Cell Biol.
88:20–23. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi F, Kouadir M and Yang Y: NALP3
inflammasome activation in protein misfolding diseases. Life Sci.
135:9–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu W, Luo Y, Dunn JH, Norris DA,
Dinarello CA and Fujita M: Dual role of apoptosis-associated
speck-like protein containing a CARD (ASC) in tumorigenesis of
human melanoma. J Invest Dermatol. 133:518–527. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Y, Kong H, Zeng X, Liu W, Wang Z, Yan
X, Wang H and Xie W: Activation of NLRP3 inflammasome enhances the
proliferation and migration of A549 lung cancer cells. Oncol Rep.
35:2053–2064. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Allen IC, TeKippe EM, Woodford RM, Uronis
JM, Holl EK, Rogers AB, Herfarth HH, Jobin C and Ting JP: The NLRP3
inflammasome functions as a negative regulator of tumorigenesis
during colitis-associated cancer. J Exp Med. 207:1045–1056. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Drexler SK, Bonsignore L, Masin M,
Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp
J and Yazdi AS: Tissue-specific opposing functions of the
inflammasome adaptor ASC in the regulation of epithelial skin
carcinogenesis. Proc Natl Acad Sci. 109:18384–18389. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Melvin JC, Holmberg L, Rohrmann S, Loda M
and Van Hemelrijck M: Serum lipid profiles and cancer risk in the
context of obesity: Four meta-analyses. J Cancer Epidemiol.
2013:8238492013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhai Z, Liu W, Kaur M, Luo Y, Domenico J,
Samson JM, Shellman YG, Norris DA, Dinarello CA, Spritz RA and
Fujita M: NLRP1 promotes tumor growth by enhancing inflammasome
activation and suppressing apoptosis in metastatic melanoma.
Oncogene. 36:3820–3830. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhong FL, Mamaï O, Sborgi L, Boussofara L,
Hopkins R, Robinson K, Szeverényi I, Takeichi T, Balaji R, Lau A,
et al: Germline NLRP1 mutations cause skin inflammatory and cancer
susceptibility syndromes via inflammasome activation. Cell.
167:187–202.e17. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Elaraj DM, Weinreich DM, Varghese S,
Puhlmann M, Hewitt SM, Carroll SM, Feldman ED, Turner EM and
Alexander HR: The role of interleukin 1 in growth and metastasis of
human cancer xenografts. Clin Cancer Res. 12:1088–1096. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pazyar N, Feily A and Yaghoobi R: An
overview of interleukin-1 receptor antagonist, anakinra, in the
treatment of cutaneous diseases. Curr Clin Pharmacol. 7:271–275.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
La E, Rundhaug JE and Fischer SM: Role of
intracellular interleukin-1 antagonist in skin carcinogenesis. Mol
Carcinog. 30:218–223. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bar D, Apte RN, Voronov E, Dinarello CA
and Cohen S: A continuous delivery system of IL-1 receptor
antagonist reduces angiogenesis and inhibits tumor development.
FASEB J. 18:161–163. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
McKenzie RC, Oran A, Dinarello CA and
Sauder DN: Interleukin-1 receptor antagonist inhibits subcutaneous
B 16 melanoma growth in vivo. Anticancer Res. 16:437–441.
1996.PubMed/NCBI
|
|
48
|
Weinreich DM, Elaraj DM, Puhlmann M,
Hewitt SM, Carroll NM, Feldman ED, Turner EM, Spiess PJ and
Alexander HR: Effect of interleukin 1 receptor antagonist gene
transduction on human melanoma xenografts in nude mice. Cancer Res.
63:5957–5961. 2003.PubMed/NCBI
|
|
49
|
Triozzi PL and Aldrich W: Effects of
interleukin-1 receptor antagonist and chemotherapy on host-tumor
interactions in established melanoma. Anticancer Res. 30:345–354.
2010.PubMed/NCBI
|
|
50
|
Hoshino T, Okamoto M, Sakazaki Y, Kato S,
Young HA and Aizawa H: Role of proinflammatory cytokine IL-18 and
IL-1beta in bleomycin-induced lung injury in humans and mice. Am J
Respir Cell Mol Biol. 41:661–670. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ledeboer A, Jekich BM, Sloane EM, Mahoney
JH, Langer SJ, Milligan ED, Martin D, Maier SF, Johnson KW,
Leinwand LA, et al: Intrathecal interleukin-10 gene therapy
attenuates paclitaxel-induced mechanical allodynia and
proinflammatory cytokine expression in dorsal root ganglia in rats.
Brain Behav Immun. 21:686–698. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Twining CM, Sloane EM, Milligan ED, Chacur
M, Martin D, Poole S, Marsh H, Maier SF and Watkins LR:
Peri-sciatic proinflammatory cytokines, reactive oxygen species,
and complement induce mirror-image neuropathic pain in rats. Pain.
110:299–309. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Surguladze D, Deevi D, Claros N, Corcoran
E, Wang W, Plym MJ, Wu Y, Doody J, Mauro DJ, Witte L, et al: Tumor
necrosis factor-alpha and interleukin-1 antagonists alleviate
inflammatory skin changes associated with epidermal growth factor
receptor antibody therapy in mice. Cancer Res. 69:5643–5647. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang X, Bi Z, Chu W and Wan Y: IL-1
receptor antagonist attenuates MAP kinase/AP-1 activation and MMP1
expression in UVA-irradiated human fibroblasts induced by culture
medium from UVB-irradiated human skin keratinocytes. Int J Mol Med.
16:1117–1124. 2005.PubMed/NCBI
|
|
55
|
van de Veerdonk FL, Netea MG, Dinarello CA
and Joosten LA: Inflammasome activation and IL-1β and IL-18
processing during infection. Trends Immunol. 32:110–116. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Abdelmeguid NE, Fakhoury R, Kamal SM and
Al Wafai RJ: Effects of Nigella sativa and thymoquinone on
biochemical and subcellular changes in pancreatic β-cells of
streptozotocin-induced diabetic rats. J Diabetes. 2:256–266. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kanter M: Nigella sativa and derived
thymoquinone prevents hippocampal neurodegeneration after chronic
toluene exposure in rats. Neurochem Res. 33:579–588. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Woo CC, Kumar AP, Sethi G and Tan KH:
Thymoquinone: Potential cure for inflammatory disorders and cancer.
Biochem Pharmacol. 83:443–451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Banerjee S, Padhye S, Azmi A, Wang Z,
Philip PA, Kucuk O, Sarkar FH and Mohammad RM: Review on molecular
and therapeutic potential of thymoquinone in cancer. Nutr Cancer.
62:938–946. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ahmad I, Muneer KM, Tamimi IA, Chang ME,
Ata MO and Yusuf N: Thymoquinone suppresses metastasis of melanoma
cells by inhibition of NLRP3 inflammasome. Toxicol Appl Pharmacol.
270:70–76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ellis LZ, Liu W, Luo Y, Okamoto M, Qu D,
Dunn JH and Fujita M: Green tea polyphenol
epigallocatechin-3-gallate suppresses melanoma growth by inhibiting
inflammasome and IL-1β secretion. Biochem Biophys Res Commun.
414:551–556. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tsai PY, Ka SM, Chang JM, Chen HC, Shui
HA, Li CY, Hua KF, Chang WL, Huang JJ, Yang SS and Chen A:
Epigallocatechin-3-gallate prevents lupus nephritis development in
mice via enhancing the Nrf2 antioxidant pathway and inhibiting
NLRP3 inflammasome activation. Free Radic Biol Med. 51:744–754.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Li D, Han T, Liao J, Hu X, Xu S, Tian K,
Gu X, Cheng K, Li Z, Hua H and Xu J: Oridonin, a promising
ent-Kaurane diterpenoid lead compound. Int J Mol Sci. 17:E13952016.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Li D, Han T, Xu S, Zhou T, Tian K, Hu X,
Cheng K, Li Z, Hua H and Xu J: Antitumor and antibacterial
derivatives of oridonin: A main composition of Dong-Ling-Cao.
Molecules. 21:E5752016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lu J, Chen X, Qu S, Yao B, Xu Y, Wu J, Jin
Y and Ma C: Oridonin induces G2/M cell cycle arrest and
apoptosis via the PI3K/Akt signaling pathway in hormone-independent
prostate cancer cells. Oncol Lett. 13:2838–2846. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wang XH, Zhang SF, Bao JT and Liu FY:
Oridonin synergizes with Nutlin-3 in osteosarcoma cells by
modulating the levels of multiple Bcl-2 family proteins. Tumour
Biol. 39:10104283177016382017.PubMed/NCBI
|
|
67
|
Xia S, Zhang X, Li C and Guan H: Oridonin
inhibits breast cancer growth and metastasis through blocking the
Notch signaling. Saudi Pharm J. 25:638–643. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhang Y, Wang L, Zi Y, Zhang L, Guo Y and
Huang Y: Oridonin effectively reverses the drug resistance of
cisplatin involving induction of cell apoptosis and inhibition of
MMP expression in human acute myeloid leukemia cells. Saudi J Biol
Sci. 24:678–686. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wang HJ, Li D, Yang FY, Tashiro S, Onodera
S and Ikejima T: Oridonin induces human melanoma A375-S2 cell death
partially through inhibiting insulin-like growth factor 1 receptor
signaling. J Asian Nat Prod Res. 10:787–798. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gu Z, Wang X, Qi R, Wei L, Huo Y, Ma Y,
Shi L, Chang Y, Li and Zhou L: Oridonin induces apoptosis in uveal
melanoma cells by upregulation of Bim and downregulation of fatty
acid synthase. Biochem Biophys Res Commun. 457:187–193. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
He H and Jiang Y: Oridonin is a covalent
NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun.
9:25502018. View Article : Google Scholar : PubMed/NCBI
|
